TLR3 and neoplasm: Translational research to date has provided an insight into the networks that activate CD8+ T cell immune response in melanoma, providing a potential treatment strategy that enhance anti-tumor immunity of anti-PD-1 Ab, such as STING agonist, AIM2 siRNA, and combination therapy of FLT3L and TLR3 agonist that target TIDCs, JAK inhibitor for exhausted CD8+ T cells, and CD122 agonist for CD8+ TRM and NK cells in tumor (Table 1).